These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9110460)

  • 21. [Treatment of chronic microvascular complications of diabetes mellitus with aldose reductase inhibitors].
    Wajchenberg BL
    Rev Assoc Med Bras (1992); 1996; 42(2):63-5. PubMed ID: 9110450
    [No Abstract]   [Full Text] [Related]  

  • 22. Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches.
    Costantino L; Rastelli G; Vianello P; Cignarella G; Barlocco D
    Med Res Rev; 1999 Jan; 19(1):3-23. PubMed ID: 9918192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Taxifolin Shows Anticataractogenesis and Attenuates Diabetic Retinopathy in STZ-Diabetic Rats
    Liu F; Ma Y; Xu Y
    Endocr Metab Immune Disord Drug Targets; 2020; 20(4):599-608. PubMed ID: 31656158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldose reductase inhibitors and diabetic kidney disease.
    Oates PJ
    Curr Opin Investig Drugs; 2010 Apr; 11(4):402-17. PubMed ID: 20336588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.
    El-Kabbani O; Wilson DK; Petrash M; Quiocho FA
    Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications.
    Yabe-Nishimura C
    Pharmacol Rev; 1998 Mar; 50(1):21-33. PubMed ID: 9549756
    [No Abstract]   [Full Text] [Related]  

  • 27. Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise?
    Boel E; Selmer J; Flodgaard HJ; Jensen T
    J Diabetes Complications; 1995; 9(2):104-29. PubMed ID: 7599349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does aldose reductase have a role in the development of the ocular complications of diabetes?
    Lightman S
    Eye (Lond); 1993; 7 ( Pt 2)():238-41. PubMed ID: 7607342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Imidazolidine/thiazolidine-acetate aldose reductase inhibitors].
    Fresneau P
    Ann Pharm Fr; 2000 Dec; 58(6):392-404. PubMed ID: 11148374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications.
    Saraswat M; Muthenna P; Suryanarayana P; Petrash JM; Reddy GB
    Asia Pac J Clin Nutr; 2008; 17(4):558-65. PubMed ID: 19114390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of the polyol pathway in the occurrence of degenerative complications of diabetes].
    Bosquet F; Grimaldi A
    Presse Med; 1986 May; 15(19):879-83. PubMed ID: 3012508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KIOM-79 inhibits aldose reductase activity and cataractogenesis in Zucker diabetic fatty rats.
    Kim J; Kim CS; Sohn E; Lee YM; Kim JS
    J Pharm Pharmacol; 2011 Oct; 63(10):1301-8. PubMed ID: 21899546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldose reductase and the etiology of diabetic cataracts.
    Varma SD
    Curr Top Eye Res; 1980; 3():91-155. PubMed ID: 6807610
    [No Abstract]   [Full Text] [Related]  

  • 34. Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
    Van Zandt MC; Jones ML; Gunn DE; Geraci LS; Jones JH; Sawicki DR; Sredy J; Jacot JL; Dicioccio AT; Petrova T; Mitschler A; Podjarny AD
    J Med Chem; 2005 May; 48(9):3141-52. PubMed ID: 15857120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of aldose reductase by nonenzymatic glycosylation.
    Srivastava SK; Ansari NH; Bhatnagar A; Hair G; Liu S; Das B
    Prog Clin Biol Res; 1989; 304():171-84. PubMed ID: 2506561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Raman spectroscopic study of the effect of aldose reductase inhibitor on experimental diabetic cataract.
    Nozawa H; Yaginuma T; Mizuno A
    Nippon Ganka Gakkai Zasshi; 1988 Jan; 92(1):194-201. PubMed ID: 3133929
    [No Abstract]   [Full Text] [Related]  

  • 37. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats.
    Kador PF; Lee JW; Fujisawa S; Blessing K; Lou MF
    J Ocul Pharmacol Ther; 2000 Apr; 16(2):149-60. PubMed ID: 10803425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecule of the month. Ruboxistaurin mesilate hydrate.
    Drug News Perspect; 2003 Dec; 16(10):691. PubMed ID: 14747848
    [No Abstract]   [Full Text] [Related]  

  • 39. Dose-dependent reduction of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by the aldose reductase inhibitor M79175.
    Neuenschwander H; Takahashi Y; Kador PF
    J Ocul Pharmacol Ther; 1997 Dec; 13(6):517-28. PubMed ID: 9436155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential use of aldose reductase inhibitors to prevent diabetic complications.
    Zenon GJ; Abobo CV; Carter BL; Ball DW
    Clin Pharm; 1990 Jun; 9(6):446-57. PubMed ID: 2114249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.